StandoutStocks.com: "Stocks that Standout" picks for today are: CGEN, ERTS, IARO, VICL

StandoutStocks.com "Stocks that Standout" picks for today are: Compugen Ltd. (NASDAQ: CGEN), Electronic Arts Inc (NASDAQ: ERTS), International Aerospace Enterprises, Inc. (OTCBB: IARO), Vical Incorporated (NASDAQ: VICL)

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Jun 30, 2009 -- Compugen Ltd. (NASDAQ: CGEN) announced today that it has received approximately $3.6 million from the private sale of 1,000,000 Evogene shares to a single purchaser. The funds generated from this transaction are expected to be used by Compugen for general corporate purposes through mid 2010. After this sale, the Company continues to hold 1,150,000 Evogene shares.

Evogene Ltd. was established as an independent company in 2002 to utilize certain of Compugen's in-silico predictive discovery capabilities in the agricultural field. Evogene securities are listed for trading on the Tel Aviv Stock Exchange (TASE:EVGN).

Martin Gerstel, Compugen's Co-CEO, said, "The accelerating validation of the power and potential for computational prediction and selection in life science product discovery by both Compugen and Evogene is very impressive. Of course, the path from computational prediction to experimental validation in the target organism is much quicker when dealing with agricultural crops than with humans. However, Compugen has now reached the stage where it is demonstrating, in a growing number of areas of key unmet medical needs, positive results for initial product candidates in animal disease models and other in vivo validation studies. As previously reported, based on this proof of our unique and broad discovery capabilities, we have recently begun discussions with a number of major pharmaceutical and biotech companies regarding various forms of strategic arrangements. As we move forward with these discussions, the funds generated through this sale of a portion of our Evogene holdings provides us with the cash required to fully support our operations through mid next year, even in the absence of any other sources of cash, and without any dilution to Compugen's shareholders."

About Compugen

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in-silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. The resulting product candidates are then validated through in vitro and in vivo experimental studies and out-licensed for further development and commercialization under various forms of revenue sharing agreements. Compugen's current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Merck Serono, Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries.

Jun 30, 2009 -- The EA Play Label of Electronic Arts Inc (NASDAQ: ERTS) and Warner Bros. Interactive Entertainment today announced that the Harry Potter and the Half-Blood Prince(TM) videogame will be available in stores across the globe this week. Available on multiple platforms, the Harry Potter and the Half-Blood Prince videogame allows players to experience all the magic, adventure and fun of the Warner Bros. Pictures' film based on J.K. Rowling's sixth book in the Harry Potter(TM) series.

In the game of Harry Potter and the Half-Blood Prince, players return to Hogwarts(TM) - reproduced from movie blueprints in exacting detail - to help Harry survive a fraught sixth year. Players will be able to master gesture-based spell-casting as they explore the Hogwarts school grounds, from the heights of the Astronomy Tower to Professor Slughorn's Potions classroom in the depths of the dungeons and iconic locations in between such as the Gryffindor(TM) common room and the Great Hall.

For the first time players can move and cast spells simultaneously, creating intense and fast-paced wizard duels as the champions from each house line up to challenge the Boy Who Lived. Players can also chase down the Golden Snitch(TM) as they take to the air as the Seeker on the Gryffindor Quidditch(TM) team. In addition to spell-casting and flying, players can put their potion-mixing skills to the test when they learn how to mix and brew magical ingredients in Potions class. Players may even get sidetracked by Ron's romantic entanglements as they journey towards the dramatic climax and discover the identity of the Half-Blood Prince.

"We are very excited by the fact that fans will be able to use Nintendo's Wii Remote(TM) controller as their wands," said Harvey Elliott, VP and GM Casual Studios, EA Play Label. "Casting charms and jinxes - Stupefy, Wingardium Leviosa, Accio and Petrificus Totalis among others - has never been easier or more realistic. This is definitely the most authentic translation from the movies and fiction that we have ever produced; the fans are going to love it!"

Developed by EA Bright Light, the team behind the worldwide success of the Harry Potter library of videogames, Harry Potter and the Half-Blood Prince videogame shipped to retailers nationwide today for the Wii(TM), PLAYSTATION(R)3 computer entertainment system, Xbox 360(R) video game and entertainment system, PlayStation(R)2 computer entertainment system, PSP(R) (PlayStation(R)Portable) system, Nintendo DS(TM), Windows PC, Mac, and mobile devices. The Wii, PLAYSTATION 3 system, Xbox 360, PlayStation 2, PC, and Mac versions are rated 'E10+' and the handheld versions are rated 'E' for Everyone by the ESRB.

About Electronic Arts

Electronic Arts Inc. (EA), headquartered in Redwood City, California, is a leading global interactive entertainment software company. Founded in 1982, the Company develops, publishes, and distributes interactive software worldwide for video game systems, personal computers, wireless devices and the Internet. Electronic Arts markets its products under four brand names: EA SPORTS(TM), EA(TM), EA Mobile(TM) and POGO(TM). In fiscal 2009, EA posted GAAP net revenue of $4.2 billion and had 31 titles that sold more than one million copies.

About Warner Bros. Interactive Entertainment

Warner Bros. Interactive Entertainment, a division of Warner Bros. Home Entertainment Group, is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all current and future platforms, including console, handheld and PC-based gaming for both internal and third party game titles.

HARRY POTTER characters, names and related indicia are trademarks of and (C) Warner Bros. Entertainment Inc. Harry Potter Publishing Rights (C) JKR. (s09)

EA, EA SPORTS, EA Mobile and POGO are trademarks or registered trademarks of Electronic Arts Inc. in the U.S. and/or other countries. Microsoft, Xbox and Xbox 360 are either trademarks or registered trademarks of the Microsoft group of companies. "PLAYSTATION", "PlayStation" and "PSP" are registered trademarks of Sony Computer Entertainment Inc. Nintendo DS and Wii are trademarks of Nintendo. All other trademarks are the property of their respective owners.

Jun 30, 2009 -- International Aerospace Enterprises, Inc. (OTCBB: IARO) today announced that the company has been Awarded a $750,000.00 USD bid award for military aircraft spare parts by the Egyptian Air Force. The award is immediate evidence that the company's International Targeted Sales Strategy is right on target as reported in the June 18, 2009 news release titled "International Aerospace Enterprises Inc. Launches Targeted Worldwide Sales Program." Mr. John Peck, IARO's CEO, reported, "The initial sales to the Egyptian Air Force is the first of over $13 million USD in our international sales pipeline."

He voiced some concern that, "IARO's management team feels that the current and future value of the company is not reflected in the company's current share price but is reflective of the decisions made by the shell's previous management." He continued by stating that he is, "confident that the Company's international sales performance and future earnings will better reflect the real value of International Aerospace Enterprises, Inc. for both our company and our shareholders."

Mr. Peck further stated, "I have some additional exciting news to report to our Shareholders. As of July 1, 2009, Mr. Saffet Uslu, our current exclusive International Sales representative, has accepted the position of President of IARO."

Mr. Uslu has a Bachelor of Science and his Master's degree in Mechanical Engineering from University of Southern California. He has obtained his dual citizenship in both the United States of America and the Republic of Turkey. His 14 years of experience in international military aircraft spare parts sales and his dual citizenship, with one of the United State's key Allies in the Middle East, makes him an exceptional addition to IARO's Management Team."

Mr. Uslu stated, "I am both excited and proud to have been asked to join IARO's Management team. To have an opportunity to be involved with an exciting company like IARO, at its foundational level, happens only once in a life time. I am dedicated and confident that IARO will produce exceptional shareholder value for in its stockholders in both the short-term and long-term through performance. I am prepared to work hard with our management team and for our shareholders."

About International Aerospace Enterprises, Inc.

International Aerospace Enterprises, Inc. (OTCBB: IARO) is an innovative and aggressive provider of discounted military aircraft spare parts for U.S. Ally partners throughout the world. The company offers inexpensive and shipment ready aircraft spare parts for both military and commercial aircraft users that meet all industry standards for quality manufacturing.

Jun 30, 2009 -- Vical Incorporated (NASDAQ: VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. The company is ready to advance directly to large-scale cGMP manufacturing of the vaccine for human clinical trials, subject to securing external funding for this program.

"Our DNA vaccine technology offers an innovative approach to dealing with pandemics," said Vijay B. Samant, President and Chief Executive Officer of Vical. "The speed of our platform both in development and manufacturing was demonstrated by our rapid completion of vaccine production and successful immunogenicity testing in animals while conventional vaccine manufacturers are still working toward production of their initial supply of H1 vaccine. We are encouraged by these compelling data with our Vaxfectin(r)-formulated DNA vaccine and we look forward to advancing to human clinical trials as soon as possible."

Vical's plasmid DNA vaccine contained the H1 hemagglutinin gene sequence provided by the U.S. Centers for Disease Control and Prevention (CDC) for the A/H1N1 influenza strain selected on April 30. The preclinical vaccine was produced by May 11 and animal testing began on May 15. In two parallel animal studies, one in mice and one in rabbits, vaccine was administered on Day 0 and Day 21, a standard regimen for pandemic influenza vaccines. Sera collected on Day 21, after a single dose of vaccine, showed clear increases over baseline hemagglutination inhibition (HI) titers in 100% of the animals, and HI titers above the protection threshold in 88% of the mice and 75% of the rabbits. Sera collected on Day 35, two weeks after the second dose, showed HI titers well above the protection threshold in 100% of the animals, ranging from 320 to 2,560 (geometric mean titer = 987) in the mice, and from 640 to 2,560 (geometric mean titer = 1,522) in the rabbits. The HI assay measures a vaccine's ability to prevent viruses from binding to cells, and HI titers of 40 or more are accepted as the threshold for potential protection against influenza viruses. The vaccine encoded H1 hemagglutinin from the swine-origin A/California/04/09 wild-type influenza virus. Vical ran the HI assay against the swine-origin A/California/07/09 x-179a reassortant influenza virus obtained from the CDC.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

For More Information Regarding Standout Stocks, Contact Jason A. Hilton: Rochester, Ny 14609 Office: (866)704-0122 Email: Jason@Newmediaadvisorsllc.com

CONTACT: Jason A. Hilton, New Media Advisors LLC Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: agricultural, air force, aircraft, animal, biotechnology, book, broker, california, cancer, cardiovascular, ceo, commercial, computer, corporate, crops, dealer, disease, distributor, dna, earnings, email, e-mail, entertainment, film, gaap, healthcare, investment, investment opinion, library, manufacturing, mechanical engineering, medical, military, movie, nasdaq, new york, online, pharmaceuticals, pipeline, president, prices, products, publisher, publishing, revenue, sales, science, securities, software, sports, standards, subscription, swine, technology, trial, turkey, university, vaccine, video, web, wireless